Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board

NEW YORK–(BUSINESS WIRE)– Regulatory News:

Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene edited CAR T-cells (UCART), today announced five new leading
experts will join the Company’s Clinical Advisory Board (CAB) in 2017
from the fields of hematologic malignancies, immunotherapy, immunology,
stem cell transplantation. The CAB serves as a strategic resource to
Cellectis as the Company enters the clinical development of allogeneic
CAR T immunotherapies, led by its wholly owned product candidate,
UCART123.

The new board members include Dr Catherine Bollard, Pr Hervé Dombret, Pr
Ola Landgren, Dr Marcela Maus and Pr Dietger Niederwieser.

“As Cellectis has recently received IND approval from the U.S. FDA to
conduct two Phase 1 clinical trials with UCART123, an allogeneic,
‘off-the-shelf’ CAR T-cell product candidate for acute myeloid leukemia
(AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), the
Company’s Clinical Advisory Board will continue to play a critical role
in establishing new and innovative immunotherapies for patients all over
the world,” said Dr. Loan Hoang-Sayag, Chief Medical Officer, Cellectis.
“As such, we are pleased these five additional hematology leading
experts have now joined the Board to further guide us in our efforts to
transform cancer treatment through gene editing.”

Professor Catherine Bollard, MBChB, MD, FRACP, FRCPA, is Chief, Division
of Allergy and Immunology and Director of the Program for Cell
Enhancements and Technologies for Immunotherapy at the Children’s
Research Institute, Children’s National Health System and The George
Washington University. A distinguished hematologist and immunotherapist,
Dr. Bollard’s research interests focus on areas that include developing
cell and gene therapies for patients with cancer and underlying immune
deficiencies.

Professor Hervé Dombret, MD, is Head of the Leukemia Unit at the Hôpital
Saint Louis, Paris, and Director of Clinical Research in the Hematology,
Immunology and Transplantation Unit, University of Paris Diderot. He is
also Director of the University Hematology Research Center in Hôpital
Saint-Louis and has a PhD in Oncogenesis. His main fields of interest
include clinical and translational research in acute myeloid leukemia,
acute lymphoblastic leukemia, myelodysplastic syndromes and chronic
myeloid leukemia.

Professor Ola Landgren, MD, is Chief of the Myeloma Service at Memorial
Sloan Kettering Cancer Center New York and Professor of Medicine at
Weill Cornell Medical College. He is a board-certified
hematologist-oncologist whose research focuses on the development of
novel treatment strategies and advanced disease monitoring. He has a
strong interest in the development of early-treatment clinical trials,
targeting high-risk smoldering myeloma. He develops new strategies
(including cell-based, molecular-based and imaging-based) and implements
advanced MRD testing in clinical trials at MSK.

Doctor Marcela V. Maus, MD, PhD, is Director of Cellular Immunotherapy
at the Massachusetts General Hospital in Boston and Assistant Professor
at Harvard Medical School. She is a board-certified
hematologist-oncologist with extensive research experience in all
aspects of pre-clinical and clinical design and use of cell therapies
and gene-modified T-cells for cancer. Dr Maus completed undergraduate
studies at MIT and her MD and PhD at Penn. As a graduate student, she
worked with Dr. Carl June on the biology of human T cell activation. She
completed residency training in internal medicine at the University of
Pennsylvania Health System, and completed fellowship training in
Hematology and Medical Oncology at Memorial Sloan Kettering Cancer
Center. Her research focuses on the pre-clinical development and
clinical translation of engineered T cell therapies.

Professor Dietger Niederwieser, MD, is Professor of Medicine, Head of
the Division of Hematology and Medical Oncology at University of Leipzig
and University Hospital. His therapeutic areas of expertise include
Clinical Immunology, Hematology and Oncology, and his research is
focused on stem cell transplantation, cell therapies and gene therapies.
He has extensive experience in health economics, outcomes research,
clinical development of innovative drugs and clinical studies.

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering – based on its flagship TALEN® products and
meganucleases as well as its pioneering electroporation PulseAgile
technology – to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.

Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group.

Disclaimer

This press release contains “forward-looking” statements that are based
on our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. The
risks and uncertainties include, but are not limited to, the risk that
the preliminary results from our product candidates will not continue or
be repeated, the risk of not obtaining regulatory approval to commence
clinical trials on the UCART product candidates, the risk that any one
or more of our product candidates will not be successfully developed and
commercialized. Further information on the risks factors that may affect
company business and financial performance, is included in filings
Cellectis makes with the Security Exchange Commission from time to time
and its financial reports. Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to
update the reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new information
becomes available in the future.

# # #

View source version on businesswire.com: http://www.businesswire.com/news/home/20170307006424/en/